“FDA will focus on regulating the subset of apps that pose the greatest risks to patients: (1) apps that are used as accessories to already-regulated medical devices, e.g., an app that alters the function or settings of an infusion pump, and; (2) apps that transform a mobile platform into an already-regulated medical device, e.g., an app that uses an attachment to a smartphone to measure blood glucose levels.”